CSL Limited
CSL.AX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$137.04B
Close$
$173.62
14.2% downside
Current Fair Value
14.2% downsideOvervalued by 14.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $137.04 Billion |
|---|---|
| Enterprise Value | $146.42 Billion |
| Annual dividend | $4.05 |
| Dividend yield | 2.02% |
| Earnings per Share | $-5.47 |
| Beta | 0.08 |
| Outstanding Shares | 478,911,979 |
Return
| Return on Equity | 3.04% |
|---|---|
| Return on Assets | 1.34% |
| Return on Invested Capital | 28.99% |
Valuation & Multiples
| P/E Ratio | -26.7 |
|---|---|
| PEG | 6.85 |
| Price to Sales | 3.11 |
| Price to Book Ratio | 5.95 |
| Enterprise Value to Revenue | 4.69 |
| Enterprise Value to EBIT | 17.85 |
| Enterprise Value to Net Income | 325 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.74 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$3.28
Consensus analyst estimateRevenue Estimate
$10.27 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 9, 2027
EPS Estimate
$5.72
Consensus analyst estimateRevenue Estimate
$12.06 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About CSL Ltd.
29,000 employees
CEO: Paul Perreault
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, t...